BridgeBio Cash And Short Term Investments vs Other Liab Analysis

BBIO Stock

USD 28.01 0.84 2.91%

BridgeBio Pharma financial indicator trend analysis is way more than just evaluating BridgeBio Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BridgeBio Pharma is a good investment. Please check the relationship between BridgeBio Pharma Cash And Short Term Investments and its Other Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

Cash And Short Term Investments vs Other Liab

Cash And Short Term Investments vs Other Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BridgeBio Pharma Cash And Short Term Investments account and Other Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between BridgeBio Pharma's Cash And Short Term Investments and Other Liab is 0.58. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Other Liab in the same time period over historical financial statements of BridgeBio Pharma, assuming nothing else is changed. The correlation between historical values of BridgeBio Pharma's Cash And Short Term Investments and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of BridgeBio Pharma are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Cash And Short Term Investments i.e., BridgeBio Pharma's Cash And Short Term Investments and Other Liab go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of BridgeBio Pharma balance sheet. This account contains BridgeBio Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by BridgeBio Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Other Liab

Most indicators from BridgeBio Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BridgeBio Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.At this time, BridgeBio Pharma's Issuance Of Capital Stock is very stable compared to the past year. As of the 1st of June 2024, Enterprise Value is likely to grow to about 8.3 B, while Selling General Administrative is likely to drop about 123 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	5.8M	6.8M	6.5M	4.2M
Total Operating Expenses	646.3M	546.1M	606.3M	442.1M

Reconciled Depreciation Total Operating Expenses

BridgeBio Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.68	0.88	-0.52	0.65	-0.49	0.89	0.67	-0.72	0.9	0.92	0.9	0.8	0.54	0.99	-0.71	0.78	0.76	0.87	0.79	0.77	0.94	0.89	1.0	0.87	0.99
Other Current Liab	0.68		0.86	-0.96	0.97	-0.93	0.68	0.97	-0.94	0.68	0.65	0.81	0.8	0.88	0.62	-0.63	0.92	0.92	0.65	0.63	0.92	0.66	0.68	0.64	0.68	0.58
Total Current Liabilities	0.88	0.86		-0.78	0.87	-0.76	0.88	0.87	-0.91	0.83	0.83	0.9	0.91	0.79	0.84	-0.79	0.97	0.93	0.76	0.89	0.94	0.88	0.88	0.86	0.84	0.81
Total Stockholder Equity	-0.52	-0.96	-0.78		-0.96	0.97	-0.58	-0.95	0.91	-0.59	-0.53	-0.71	-0.75	-0.9	-0.43	0.51	-0.87	-0.9	-0.47	-0.53	-0.9	-0.49	-0.58	-0.47	-0.59	-0.4
Other Liab	0.65	0.97	0.87	-0.96		-0.95	0.69	0.98	-0.98	0.63	0.61	0.77	0.8	0.94	0.58	-0.73	0.94	0.89	0.58	0.71	0.9	0.67	0.69	0.61	0.68	0.54
Net Tangible Assets	-0.49	-0.93	-0.76	0.97	-0.95		-0.61	-0.97	0.88	-0.47	-0.42	-0.73	-0.77	-0.86	-0.39	0.62	-0.87	-0.89	-0.51	-0.52	-0.88	-0.54	-0.61	-0.43	-0.65	-0.35
Property Plant And Equipment Net	0.89	0.68	0.88	-0.58	0.69	-0.61		0.75	-0.71	0.7	0.71	0.92	0.95	0.51	0.85	-0.76	0.8	0.78	0.9	0.73	0.79	0.91	1.0	0.87	0.97	0.84
Net Debt	0.67	0.97	0.87	-0.95	0.98	-0.97	0.75		-0.94	0.61	0.58	0.84	0.85	0.88	0.58	-0.73	0.94	0.93	0.67	0.66	0.93	0.71	0.75	0.62	0.76	0.55
Retained Earnings	-0.72	-0.94	-0.91	0.91	-0.98	0.88	-0.71	-0.94		-0.72	-0.72	-0.76	-0.8	-0.96	-0.66	0.76	-0.96	-0.89	-0.57	-0.81	-0.89	-0.72	-0.71	-0.69	-0.67	-0.62
Accounts Payable	0.9	0.68	0.83	-0.59	0.63	-0.47	0.7	0.61	-0.72		0.99	0.77	0.67	0.62	0.9	-0.46	0.73	0.76	0.63	0.71	0.77	0.72	0.7	0.9	0.67	0.89
Cash	0.92	0.65	0.83	-0.53	0.61	-0.42	0.71	0.58	-0.72	0.99		0.74	0.65	0.61	0.93	-0.52	0.73	0.72	0.63	0.77	0.73	0.76	0.71	0.93	0.66	0.92
Non Current Assets Total	0.9	0.81	0.9	-0.71	0.77	-0.73	0.92	0.84	-0.76	0.77	0.74		0.91	0.59	0.84	-0.71	0.86	0.9	0.91	0.66	0.9	0.9	0.92	0.86	0.96	0.83
Non Currrent Assets Other	0.8	0.8	0.91	-0.75	0.8	-0.77	0.95	0.85	-0.8	0.67	0.65	0.91		0.61	0.73	-0.69	0.88	0.89	0.83	0.69	0.9	0.81	0.95	0.76	0.92	0.71
Other Assets	0.54	0.88	0.79	-0.9	0.94	-0.86	0.51	0.88	-0.96	0.62	0.61	0.59	0.61		0.49	-0.67	0.87	0.78	0.34	0.73	0.79	0.55	0.51	0.52	0.49	0.45
Cash And Short Term Investments	0.99	0.62	0.84	-0.43	0.58	-0.39	0.85	0.58	-0.66	0.9	0.93	0.84	0.73	0.49		-0.67	0.71	0.68	0.84	0.78	0.69	0.91	0.85	1.0	0.81	1.0
Common Stock Total Equity	-0.71	-0.63	-0.79	0.51	-0.73	0.62	-0.76	-0.73	0.76	-0.46	-0.52	-0.71	-0.69	-0.67	-0.67		-0.79	-0.62	-0.66	-0.87	-0.63	-0.88	-0.76	-0.69	-0.72	-0.63
Common Stock Shares Outstanding	0.78	0.92	0.97	-0.87	0.94	-0.87	0.8	0.94	-0.96	0.73	0.73	0.86	0.88	0.87	0.71	-0.79		0.95	0.69	0.84	0.96	0.81	0.8	0.75	0.77	0.68
Non Current Liabilities Total	0.76	0.92	0.93	-0.9	0.89	-0.89	0.78	0.93	-0.89	0.76	0.72	0.9	0.89	0.78	0.68	-0.62	0.95		0.7	0.67	1.0	0.72	0.78	0.71	0.79	0.65
Other Current Assets	0.87	0.65	0.76	-0.47	0.58	-0.51	0.9	0.67	-0.57	0.63	0.63	0.91	0.83	0.34	0.84	-0.66	0.69	0.7		0.58	0.71	0.9	0.9	0.84	0.9	0.84
Other Stockholder Equity	0.79	0.63	0.89	-0.53	0.71	-0.52	0.73	0.66	-0.81	0.71	0.77	0.66	0.69	0.73	0.78	-0.87	0.84	0.67	0.58		0.69	0.84	0.73	0.8	0.62	0.74
Total Liab	0.77	0.92	0.94	-0.9	0.9	-0.88	0.79	0.93	-0.89	0.77	0.73	0.9	0.9	0.79	0.69	-0.63	0.96	1.0	0.71	0.69		0.74	0.79	0.72	0.8	0.66
Net Invested Capital	0.94	0.66	0.88	-0.49	0.67	-0.54	0.91	0.71	-0.72	0.72	0.76	0.9	0.81	0.55	0.91	-0.88	0.81	0.72	0.9	0.84	0.74		0.91	0.93	0.89	0.9
Property Plant And Equipment Gross	0.89	0.68	0.88	-0.58	0.69	-0.61	1.0	0.75	-0.71	0.7	0.71	0.92	0.95	0.51	0.85	-0.76	0.8	0.78	0.9	0.73	0.79	0.91		0.87	0.97	0.84
Total Current Assets	1.0	0.64	0.86	-0.47	0.61	-0.43	0.87	0.62	-0.69	0.9	0.93	0.86	0.76	0.52	1.0	-0.69	0.75	0.71	0.84	0.8	0.72	0.93	0.87		0.83	0.99
Non Current Liabilities Other	0.87	0.68	0.84	-0.59	0.68	-0.65	0.97	0.76	-0.67	0.67	0.66	0.96	0.92	0.49	0.81	-0.72	0.77	0.79	0.9	0.62	0.8	0.89	0.97	0.83		0.81
Net Working Capital	0.99	0.58	0.81	-0.4	0.54	-0.35	0.84	0.55	-0.62	0.89	0.92	0.83	0.71	0.45	1.0	-0.63	0.68	0.65	0.84	0.74	0.66	0.9	0.84	0.99	0.81

Click cells to compare fundamentals

BridgeBio Pharma Account Relationship Matchups

BridgeBio Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	631.7M	703.6M	1.0B	623.0M	546.4M	641.2M
Other Current Liab	4.1M	5.6M	113.3M	94.4M	123.0M	129.1M
Total Current Liabilities	52.4M	91.9M	130.1M	117.8M	143.8M	90.7M
Total Stockholder Equity	408.5M	57.9M	(870.4M)	(1.3B)	(1.4B)	(1.3B)
Other Liab	3.5M	7.9M	22.1M	26.6M	30.6M	32.2M
Net Tangible Assets	408.5M	59.5M	(915.3M)	(1.3B)	(1.2B)	(1.1B)
Property Plant And Equipment Net	5.6M	36.8M	46.0M	25.2M	19.8M	21.3M
Net Debt	(264.0M)	139.7M	1.3B	1.3B	1.4B	1.4B
Retained Earnings	(440.0M)	(888.8M)	(1.4B)	(1.9B)	(2.6B)	(2.4B)
Accounts Payable	8.9M	8.9M	11.9M	11.6M	10.7M	10.6M
Cash	363.8M	356.1M	393.8M	376.7M	375.9M	376.3M
Non Current Assets Total	31.9M	60.8M	173.1M	117.8M	68.8M	74.3M
Non Currrent Assets Other	(4.9M)	21.3M	33.0M	20.2M	22.6M	14.8M
Other Assets	26.3M	23.9M	33.0M	140.8M	161.9M	170.0M
Cash And Short Term Investments	577.1M	607.1M	787.5M	428.3M	434.9M	528.5M
Common Stock Total Equity	124K	125K	154K	157K	141.3K	134.2K
Common Stock Shares Outstanding	105.1M	118.0M	144.4M	147.5M	162.8M	135.5M
Liabilities And Stockholders Equity	631.7M	703.6M	1.0B	623.0M	546.4M	641.2M
Non Current Liabilities Total	103.3M	503.8M	1.7B	1.8B	1.7B	1.0B
Other Current Assets	22.6M	35.7M	101.3M	21.9M	24.3M	32.8M
Other Stockholder Equity	845.9M	946.3M	566.5M	663.7M	1.2B	664.4M
Total Liab	155.7M	595.7M	1.9B	1.9B	1.9B	1.1B
Net Invested Capital	500.2M	535.2M	833.4M	453.0M	372.5M	397.1M
Property Plant And Equipment Gross	5.6M	36.8M	46.0M	25.2M	19.8M	21.3M
Total Current Assets	599.8M	642.8M	839.7M	505.2M	477.6M	566.9M
Accumulated Other Comprehensive Income	254K	192K	(132K)	(328K)	31K	32.6K
Non Current Liabilities Other	3.5M	24.2M	39.5M	26.6M	9.4M	16.3M
Net Working Capital	508.2M	547.2M	709.6M	387.4M	333.7M	469.5M
Common Stock	124K	125K	154K	157K	181K	172.0K
Property Plant Equipment	5.6M	20.3M	46.0M	14.6M	16.8M	16.2M
Short Long Term Debt Total	99.8M	495.8M	1.7B	1.7B	1.7B	1.1B
Long Term Debt	91.8M	475.9M	1.7B	1.7B	1.7B	1.1B
Long Term Debt Total	91.8M	475.9M	1.7B	1.7B	2.0B	2.1B
Capital Stock	124K	125K	154K	157K	181K	172.0K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock:

How To Invest In BridgeBio

Details

Is BridgeBio Stock a good investment?

Details

What is BridgeBio Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for BridgeBio Stock analysis

When running BridgeBio Pharma's price analysis, check to measure BridgeBio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma is operating at the current time. Most of BridgeBio Pharma's value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma's price. Additionally, you may evaluate how the addition of BridgeBio Pharma to your portfolios can decrease your overall portfolio volatility.

	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios

Is BridgeBio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.23)

Revenue Per Share

1.291

Quarterly Revenue Growth

114.619

Return On Assets

(0.40)

Return On Equity

(17.90)

The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BridgeBio Cash And Short Term Investments vs Other Liab Analysis

Cash And Short Term Investments vs Other Liab

Cash And Short Term Investments vs Other Liab Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Other Liab

BridgeBio Pharma fundamental ratios Correlations

BridgeBio Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BridgeBio Pharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for BridgeBio Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.99	Total Assets

Retained Earnings	- 0.98	Other Liab
Net Debt	- 0.97	Net Tangible Assets
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Other Assets	- 0.96	Retained Earnings
Other Liab	- 0.96	Total Stockholder Equity
Total Stockholder Equity	- 0.96	Other Current Liab